Differences in Transcriptomic Profiles of Brain and Thyroid Tumors with NTRK Gene Rearrangement

For tumors with chimericNTRK genes, entrectinib and larotrectinib can be prescribed regardless of tumor localization. We compared changes in the transcriptional activity of genes in brain tumors (BT) and thyroid cancer (TC) with rearrangement (NTRK+) and without rearrangement (NTRK-) of theNTRK genes using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. We revealed an increase in the transcription of theJUN gene inNTRK+ samples in comparison withNTRK- samples: by 1.6 times for BT (p=0.239) and by 2.5 times for TC (p=0.003). The transcription of eightHOX genes inNTRK+ BT samples was also increased (by 85-725 times,p<0.05) in comparison withNTRK-. InNTRK+ TC samples, the level ofmiR-31 andmiR-542 was statistically significantly higher (by 3 and 2.5 times, respectively) than inNTRK-samples. For theNTRK+ BT samples, the levels ofmiR-10b,miR-182, andmiR-21 more than 5-fold surpassed the corresponding values inNTRK-samples (p<0.05). These findings reflect differences in activation of gene transcription resulting fromNTRK gene rearrangement in BT and TC.
Source: Bulletin of Experimental Biology and Medicine - Category: Biology Source Type: research